C&EN

The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer

Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States ...